Clinuvel Pharmaceuticals (CUV) H1 2026 earnings summary

Executive summary

• Revenue grew 4% year-over-year to $36.93 million for the half year ended 31 December 2025, marking a record first-half result and the 20th consecutive profitable period.

• Profit after tax was $10.44 million, down 26% year-over-year, reflecting increased investment in R&D and business expansion.

• Cash reserves rose 4% to $233 million, supporting self-funded growth, ongoing operations, and future initiatives.

• The company remains debt-free for 21 years, with no equity dilution since 2016 and a self-financed expansion strategy.

• EMA approved year-round SCENESSE® treatment for EPP, and an ADR Level II uplisting to Nasdaq is underway.

Financial highlights

• Total expenses rose 22% to $25.98 million, mainly due to higher R&D, personnel, clinical, commercial, and corporate costs.

• Interest income increased 14% to $5.3 million, driven by higher cash balances and favorable term deposit rates.

• Other income saw a negative swing of $4.6 million due to unrealized FX translation losses.

• Dividend of 5.0 cents per share fully franked was paid in September 2025.

• Net assets increased to just under $250 million, with net tangible asset backing per ordinary security at $4.93.

Outlook and guidance

• Sufficient funds to run programs through 2028, with continued investment in R&D, manufacturing, and commercial expansion.

• Anticipates topline results for CUV105 vitiligo study and start of CUV107 in H2 2026, plus preclinical readout for new controlled-release formulation in H1 2026.

• Uplisting to Nasdaq and expanded commercial activities planned, with higher second-half revenues expected due to seasonal demand.

• Key regulatory milestones expected in 2026, including EMA engagement for adolescent EPP and Health Canada decision.